secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0000886163-24-000045
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve 9.7M share stock plan amendment, re-elect all eight directors
--------------------------------------------------------------------------------

- All eight director nominees re-elected to one-year terms; votes for ranged from 12.3M to 15.3M.
- Ratification of Ernst & Young as independent auditor for FY2024 approved (15.9M for, 0.8M against).
- Non-binding advisory say-on-pay resolution approved with 14.3M votes for.
- Restated 2002 Stock Incentive Plan approved, authorizing up to 9,713,754 common shares.
- Company will cease granting awards under the 2022 Employment Inducement Plan after meeting date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000045/0000886163-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000045/lgnd-20240614.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer